Dr. Soon T. Lee, MD

Dr. Lee practices at East Bay Retina Consultants, Inc. in Oakland, California.

Dr. Lee's NPI, 1952394553, was assigned on August 30, 2005. Dr. Lee graduated from University of Melbourne Faculty of Medicine in 1984. Dr. Lee holds California license A443122.

Dr. Lee's primary practice is East Bay Retina Consultants, Inc., at 3300 Telegraph Ave, Oakland, CA 94609-3028. The practice phone is (510) 444-1600.

Dr. Lee's primary practice is East Bay Retina Consultants, Inc. in Oakland, California. Dmand AI also links Dr. Lee to 1 medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lee practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Lee's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Lee is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Lee's licenses on file in 2 states: California and Florida.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, conjunctivitis, dry eye, eyelid inflammation, glaucoma and hypertensive retinopathy among the conditions Dr. Lee treats.

CMS data shows 10,691 Medicare services from Dr. Lee across 20 procedure codes in 2024, for 1,165 Medicare patients. Medicare paid $1,471,622 for them. Every service was in an office.

CMS counts 1,165 Medicare patients who saw Dr. Lee in 2024. The largest group is 75 to 84, with 464 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 35% are also on Medicaid. Their average risk score is 1.40, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lee's median patient age at 72, with 52% women.

In 2024, Dr. Lee wrote 386 Medicare Part D claims for 89 patients. 60% of them were for generic drugs. CMS names the drug for 308 of them, across 8 drugs with 11 or more claims each, at $12,277 in total drug cost. In 2023, CMS named 331 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Lee for performance year 2024, reported as part of a group. Dr. Lee accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 6 papers to Dr. Lee. The most frequent topics are Fluorescein Angiography, Fundus Oculi and Retinal Diseases. Dr. Lee has published most often in Retina. Dr. Lee's most frequent co-authors are Everett Ai, MD, Daniel A. Brinton, MD and Emmett T. Cunningham, MD, MPH, PhD.

Dmand AI links Dr. Lee to 4 clinical trials, 3 of them phase 3 studies. Conditions studied include Macular Degeneration, Choroidal Neovascularization and Geographic Atrophy.

CMS Open Payments shows 29 general payments to Dr. Lee from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 90% of the total. Carl Zeiss Meditec, Inc. paid the most, $12,006.

Dmand AI lists 14 awards for Dr. Lee, most recently Best Doctors in America in 2001.

Dr. Lee graduated from University of Melbourne Faculty of Medicine in 1984. Dr. Lee is a member of AAO, ASRS and CMA.

Dr. Lee is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.